期刊文献+

我国罕见病界定标准初探 被引量:25

Preliminary study on Chinese standards for defining rare diseases
下载PDF
导出
摘要 目的:为我国罕见病界定标准的确立提供参考。方法:比较欧美日等国家和地区罕见病定义并提炼出界定标准,分析影响各标准制定的关键因素,进而提出确立我国罕见病界定标准的建议。结果与结论:一个国家罕见病界定标准的制定受社会经济发展水平、医学发展水平、社会保障水平等因素影响,建议我国采用患病数、疾病严重程度、罕用药经济学标准来界定罕见病。 Objective:To suggest approaches for the establishment of Chinese standards for defining rare diseases and advance corresponding Chinese legislation. Methods:By comparing the standards for defining rare diseases in Europe, the United States, and other countries and studying key influencing factors of standards, this paper proposes suggestions for the establishment of proper Chinese standards for defining rare. Results and Conclusion:Social and economic development levels, medical development levels and social security levels influence the establishment of standards. It is recommended that the national conditions should be taken into consideration and the number of patients, severity of the diseases and economic indicators of orphan drugs be used to define rare diseases in China.
作者 陈永法 伍琳
出处 《中国卫生政策研究》 CSCD 2014年第10期16-20,共5页 Chinese Journal of Health Policy
关键词 罕见病 罕用药 界定标准 立法 Rare diseases Orphan drug Definition standards Legislation
  • 相关文献

参考文献10

二级参考文献31

  • 1李中华.美国新药研发的资金来源筹措及其工具[J].中国医药技术经济与管理,2007(1):35-40. 被引量:7
  • 2万仁甫,徐伟亚.建立医院罕见病信息管理制度的思考[J].中华医院管理杂志,2006,22(4):275-278. 被引量:11
  • 3赵瑾璐,无.发挥政府在促进企业成为自主创新主体中的作用[J].决策咨询通讯,2006,17(6):35-37. 被引量:3
  • 4CAM YL.A Europe for People Living With Rare Diseases:Are we making the case?[C/OL].//Empowering the Rare Disease Community European Awareness Conference & Eurordis Meeting.Eurordis,Ireland(2004-06-26).http://www.eurordis.org/IMG/ppt/05_yann le cam.ppt.
  • 5HAFFNER ME.The current environment in orphan drug development[J].Drug Inf J,2003,37(4):373-379.
  • 6The Orphan Drug ACT:Implementation and Impact[R/OL]//USA Department of Health and Human services/Office of Inspector General (OEI-09-00-00380,5/01) (2004-10-21).http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf.
  • 7The orphan drug program and improving community access to effective drugs for rare diseases[R/OL]//Australia therapeutic goods administration (2004-08-31).http://www.tga.gov.au/docs/pdf/orphrev.pdf.html.
  • 8ROHDE DD.The orphan drug act:an engine of innovation? At what cost?[J].Food Drug Cosmet Law J,2000,55(1):125-143.
  • 9Despite incentives,regulatory barriers impede orphan drug development in Japan[EB/OL].(2003-03-12).http://www.ey.com/global/download.nsf/Denmark/LSN_March2003.pdf.
  • 10EMEA.Comp report to the commission in relation to article 10 of regulation 141/2000 on orphan orphan medicinal products[EB/OL].(2005-07-25).http://www.emea.eu.int/pdfs/human/comp/3521805 en.pdf.

共引文献113

同被引文献197

引证文献25

二级引证文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部